$PSEC

Prospect Capital Announces Special Meeting Update

Prospect Capital Corporation (NASDAQ: PSEC) said it held its special stockholders’ meeting on June 9, 2026. The proposals were outlined in its March 11, 2026 definitive proxy statement. As of March 11, 2026, it reported 486,484,945 common shares outstanding and multiple preferred series. The meeting was adjourned to June 23, 2025 at 5:00 p.m. ET.

Original reporting
Published Jun 9, 2026, 9:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 9:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Prospect Capital Announces Special Meeting Update — source image
Decision brief

The 30-second read

$PSECNeutralLow
01

Why it matters

This is primarily a procedural update on the special meeting and adjournment timing; it may influence near-term expectations around shareholder approval timing for the proxy proposals.

02

Market read

Near-term trading impact is likely limited unless the adjournment implies vote uncertainty; no proposal outcomes or revised economics are provided here.

03

What to watch

Traders may need to check the definitive proxy and any subsequent filings for proposal specifics, vote results, or amendments—this release does not provide them.

Relevance 4/10Novelty 3/10Timing: Special meeting held June 9, 2026; adjourned to June 23, 2025 (per release).

Background

Prospect Capital is a business development company (BDC) and the release references its March 11, 2026 definitive proxy for proposals considered at a special meeting.

Company-level read

Ticker impact

$PSECNeutralMedium confidence
Context

Prospect Capital held its special stockholder meeting and adjourned it to June 23, 2025, per its proxy dated March 11, 2026.

Expected impact

Likely limited/short-lived unless the adjournment signals vote uncertainty or changes to the proposals (not disclosed in this text).

Evidence & confidence

The article discloses meeting timing and share/vote counts, but does not state outcomes, revised terms, or new catalysts beyond the adjournment.

Market effects

Minimal—BDC meeting mechanics are generally idiosyncratic and not a sector-wide catalyst from this text alone.

None indicated beyond US small/mid-cap corporate governance flow.

None indicated.

Counterpoint

The adjournment date could reflect unresolved proxy solicitation or contested votes, which may increase volatility into the rescheduled meeting even without new deal terms.

Key entities

  • Prospect Capital Corporation

    BDC that held a special stockholder meeting and adjourned it to a later date per its proxy.

Related articles

$PSECMed

Prospect Capital Corp (PSEC) (Q4 2026) Earnings Call Highlights: Consistent NII

Prospect Capital Corp (PSEC) reported Q4 2026 results with flat net investment income at $78M, NAV at $5.71/share, and a 28.6% net debt-to-assets ratio. The company highlighted a successful exit of Valley Electric, AI initiatives, and middle-market lending performance. Real estate exposure is 14% of investments, and liquidity remains strong with $1.6B in cash and undrawn revolver commitments.

$PSECHigh

PROSPECT CAPITAL CORP (PSEC): Results of Operations and Financial Condition

PROSPECT CAPITAL CORP (PSEC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Prospect Capital Announces June 2026 Results NEW YORK, August 20, 2026 (GLOBE NEWSWIRE) – Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) today announced financial results for our fiscal quarter and fiscal year ended June 30, 2026. FINANCIAL

$PSECMed

Palmer Square Capital BDC Inc. Q2 2026 Earnings Call Summary

Palmer Square Capital BDC Inc. reported Q2 2026 results, citing disciplined capital allocation and a subdued M&A backdrop. NAV per share fell to $13.21 on BSL fair value moves; nonaccrual rate was 0.29%. Management expects a BDC CLO reset to be accretive from Q4 2026 and set a Q3 base dividend of $0.36 plus potential supplements. It expanded a $30m share repurchase program.

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

$XOMMed

Piper Sandles Sees ExxonMobil (XOM) Heading Toward New Highs

Piper Sandler raised its price target for ExxonMobil (XOM) to $185, citing strong fundamentals, cost savings, and growth in Guyana. XOM's Q2 earnings beat expectations, with high free cash flow and shareholder returns. However, risks include exposure to Middle East conflicts and potential crude price normalization. XOM's stock has risen 30% in 2026, with a 16% upside implied by the new target.